Clinical Trials Browser

Interventional × Lung Neoplasms × tanespimycin × Clear all

Lung Neoplasms

NCT01362400 2014-05-19

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

226 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT00004065 2013-06-24

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Blast Crisis, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Leukemia, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Esthesioneuroblastoma, Olfactory, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00431015 2012-12-10

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

IPI-504 in NSCLC Patients With ALK Translocations

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)